Editorial

Can the President Still Cure Cancer?

Forty- five years ago, in a room filled with congressional members from both sides of the isle, distinguished guests,...

Early Detection: The New Cancer Paradigm

A seemingly healthy patient walks into the doctor’s office for a routine checkup. The doctor says: "I have good...

Contract Manufacturing of Antibody-drug Conjugates – A Growing Market

The demand for manufacturing capacity of antibody-drug conjugates (ADCs), which includes a highly potent cytotoxic drug linked to a monoclonal...

Developing the Next Generation of Clinically Successful Antibody-drug Conjugates

Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers...

Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament

Earlier this month, during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held in...

The Challenge of Antibody-drug Conjugates (ADC) Characterization

Therapeutic antibody–drug conjugates or ADCs (also known as immunoconjugates) selectively kill tumor cells that overexpress a specific target antigen...

How Personalization Will Improve Healthcare

While healthcare reform has many challenges, there are some very positive things happening behind the scenes. One of them...

CPhI Worldwide 2015, Antibody-drug Conjugates and Market Progression

Ahead of CPhI Worldwide 2015, CPhI expert panelist, Vivek Sharma, CEO of Pharma Solutions at Piramal, analyses the challenges...

Event Preview: CPhI Worldwide 2015

CPhI Worldwide 2015 returns to Madrid, Spain, for the 26th edition, bringing with it the booming pharmaceutical industry ready...

New Anticancer Drugs Show Promise in the Treatment of Solid Tumors

A number of novel anticancer drugs are showing very promising results in the treatment of solid cancers. These cancers, including...

FEATURED RESOURCES